** Shares of medical equipment maker Thermo Fisher TMO.N rise 1.2% to $574.94 premarket
** Co beats Q4 profit and revenue estimates on improved demand for its products and services used in developing therapies
** Posts Q4 adj. profit of $6.10 per share, beating estimates of $5.94, as per data compiled by LSEG
** Reports Q4 rev of $11.40 billion, ahead of estimates of $11.28 billion
** Co says will provide 2025 forecast on earnings call
** Stock had fallen 2% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。